Maternal bile acid transporter deficiency promotes neonatal demise

Yuanyuan Zhang1, Fei Li2, Yao Wang1

  • 1Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105, USA.

Nature Communications
|September 30, 2015
PubMed

Insights

Maternal cholestasis during pregnancy causes neonatal death by affecting lung development. Targeting pulmonary bile acids may improve neonatal survival in cases of intrahepatic cholestasis of pregnancy (ICP).

Area of Science:

  • Reproductive biology
  • Neonatal physiology
  • Hepatology

Background:

  • Intrahepatic cholestasis of pregnancy (ICP) affects 0.4-5% of pregnancies globally, leading to adverse neonatal outcomes.
  • Neonatal mortality is a significant concern in ICP, necessitating research into underlying mechanisms.

Purpose of the Study:

  • To investigate the mechanisms by which maternal cholestasis leads to neonatal death.
  • To identify potential therapeutic targets for improving neonatal survival in ICP.

Main Methods:

  • Utilized a mouse model with Abcb11 deficiency to induce maternal cholestasis.
  • Analyzed pulmonary bile acid levels and surfactant structure in neonates.
  • Investigated the effect of Nr1i2 deficiency in combination with Abcb11 deficiency.

Main Results:

  • Maternal cholestasis (Abcb11 deficiency) caused neonatal death within 24 hours due to pulmonary hypoxia and atelectasis.
  • Neonates exhibited elevated pulmonary bile acids and disrupted pulmonary surfactant structure.
  • Co-deficiency of Abcb11 and Nr1i2 reduced maternal bile acids and improved neonatal survival.

Conclusions:

  • Pulmonary bile acids are identified as a key factor disrupting pulmonary surfactant structure in neonates of ICP.
  • Findings suggest therapeutic interventions targeting pulmonary bile acids could ameliorate neonatal respiratory failure in ICP.
  • This study provides critical insights into the pathophysiology of neonatal respiratory distress associated with elevated maternal bile acids.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
732
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.5K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
333